"Momordica charantia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A plant species of the family CUCURBITACEAE. It is a source of ribosome-inactivating proteins and triterpene glycosides.
| Descriptor ID |
D029777
|
| MeSH Number(s) |
B01.650.940.800.575.912.250.300.655.249
|
| Concept/Terms |
Momordica charantia- Momordica charantia
- Momordica charantias
- charantias, Momordica
- Bitter Melon
- Bitter Melons
- Melon, Bitter
- Melons, Bitter
- Gourd, Bitter
- Bitter Gourd
- Bitter Gourds
- Gourds, Bitter
- Karela
- Karelas
|
Below are MeSH descriptors whose meaning is more general than "Momordica charantia".
Below are MeSH descriptors whose meaning is more specific than "Momordica charantia".
This graph shows the total number of publications written about "Momordica charantia" by people in this website by year, and whether "Momordica charantia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Momordica charantia" by people in Profiles.
-
Singh SK, Singh S, Singh R. Targeting novel coronavirus SARS-CoV-2 spike protein with phytoconstituents of Momordica charantia. J Ovarian Res. 2021 Sep 27; 14(1):126.
-
Nerurkar PV, Orias D, Soares N, Kumar M, Nerurkar VR. Momordica charantia (bitter melon) modulates adipose tissue inflammasome gene expression and adipose-gut inflammatory cross talk in high-fat diet (HFD)-fed mice. J Nutr Biochem. 2019 06; 68:16-32.
-
Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila). 2011 Dec; 4(12):2122-30.
-
Snee LS, Nerurkar VR, Dooley DA, Efird JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management. Nutr J. 2011 Jul 28; 10:78.
-
Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, Shah P, Feher D, Williams PG, Nerurkar VR. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011 Jun 03; 8:64.
-
Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010 Jun 29; 10:34.
-
Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010 Jun; 27(6):1049-53.
-
Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010 Mar 01; 70(5):1925-31.
-
Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008 Oct; 100(4):751-9.
-
Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, Nerurkar VR. Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol. 2006 Aug; 148(8):1156-64.